Impact of Co-Mutations on Treatment Strategies in in EGFR-Mutant NSCLC

Heather Wakelee, MD, and Helena Yu, MD, examine emerging data on co-mutations, particularly TP53, and their implications for prognosis and treatment selection. They discuss whether TP53 status should influence frontline intensification and how molecular complexity may shape sequencing strategies. The discussion also considers the generalizability of data from Chinese analyses to broader, more diverse patient populations.